Chronic kidney disease (CKD) due to diabetes occurs in 20 to 40% of patients and is the most common cause of end-stage renal disease.1
Quest Diagnostics’ Diabetes, Advancing CKD Management Panel provides you with a way to offer comprehensive annual testing to diabetes patients who may be at risk for CKD or who have progressed to stage 3 or 4 CKD.
The Nonalcoholic Fatty Liver Disease (NAFLD) Score Panel identifies diabetes patients who are at risk for developing serious liver disease. A complete fibrosis score is calculated and provided at no additional cost.
This information is provided for informational purposes only and is not intended as medical advice. A physician’s test selection and interpretation, diagnosis, and patient management decisions should be based on his/her education, clinical expertise, and assessment of the patient.
Diabetes & prediabetes